Johnson & Johnson
J&J uses FDA Priority Review Voucher to snag psoriasis approval
July 14, 2017Medical Communications, Sales and Marketing Janssen, Johnson & Johnson, Tremfya, biotech, drugs, pharma, pharmaceutical
The FDA has handed out another approval, as the agency now easily surpasses last year’s figure of 22 already, this …
Johnson & Johnson face major lawsuit over vaginal mesh
July 4, 2017Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, lawsuit, vaginal mesh
Johnson & Johnson will face a lawsuit after 700 Australian women launched a class action suit over the failures of …
Making strides in hepatitis
June 19, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Johnson & Johnson
Pharmafocus caughtup with Lawrence Blatt, Janssen’s Global Therapeutic Area Head, Infectious Diseases and Vaccines, to discuss the progress being made in the …
Latest prostate cancer research could provide boost for J&J
June 5, 2017Research and Development, Sales and Marketing CRUK, Cancer, Johnson & Johnson, prostate cancer
Research funded by Cancer Research UK has found that abiraterone added to hormone therapy improved survival by over a third …
J&J lines up its Global Head for Actelion
May 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Janssen, Johnson & Johnson
The deal is not yet complete but the last steps are assumed to be a formality – at least Johnson …
FDA demands new warnings for J&J diabetes drug over amputation risk
May 17, 2017Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, diabetes
Johnson & Johnson has found itself in deep water again over the potentially harmful effects of its products. This time …
J&J chalks up another defeat in $110 million talc-cancer case
May 5, 2017Medical Communications Johnson & Johnson, baby powder
Johnson & Johnson has suffered another defeat in a lawsuit against its talcum powder product. The latest case stands as …
J&J acquires Neuravi to bolster neuro business
April 11, 2017Manufacturing and Production, Sales and Marketing Johnson & Johnson, Neuravi
Johnson & Johnson’s neurosurgery and neurovascular unit, Codman Neuro, has made the move to acquire Galway-based company, Neuravi. The exact …
EMA green lights Actelion’s drug after patient deaths scare
April 10, 2017Sales and Marketing Actelion, Johnson & Johnson, Uptravi
The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related …
Closure of Scottish J&J plant threatens 400 staff
March 10, 2017Manufacturing and Production, Medical Communications J&J, JJ, Johnson & Johnson
Johnson & Johnson has announced its intention to shut down its surgical suture manufacturing facility in Livingston, Scotland which sees …
J&J latest pharma firm to volunteer pricing data
February 28, 2017Manufacturing and Production, Medical Communications J&J, JJ, Johnson & Johnson
Johnson & Johnson released its pricing data, as promised, in February and it has simply revealed that its average price …
Pfizer’s Remicade biosimilar displays similar efficacy
February 22, 2017Research and Development Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in …
The March 2017 issue of Pharmafocus is now live!
February 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo
The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …
Integra bids $1.045 billion for J&J’s neurosurgery business
February 16, 2017Sales and Marketing Codman, Integra, J&J, JJ, Johnson & Johnson
Integra, a medical technology company, have announced that it has made a binding offer to acquire Johnson & Johnson’s Codman …
Five most talked about mergers and acquisitions of 2016
January 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma
2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …
Latest content
Five Facts about cardiovascular disease
